Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia—A multicenter cohort study Correspondence


Authors: Bewersdorf, J. P.; Shimony, S.; Shallis, R. M.; Liu, Y.; Berton, G.; Schaefer, E. J.; Zeidan, A. M.; Goldberg, A.; Stein, E.; Marcucci, G.; Bystrom, R. P.; Lindsley, R. C.; Chen, E. C.; Ramos, J.; Stein, A.; Pullarkat, V.; Aldoss, I.; DeAngelo, D. J.; Neuberg, D. S.; Stone, R. M.; Garciaz, S.; Ball, B.; Stahl, M.
Title: Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia—A multicenter cohort study
Keywords: unclassified drug; gene mutation; overall survival; monotherapy; cytarabine; letter; cohort analysis; cytogenetics; hematopoietic stem cell transplantation; health care quality; multicenter study; daunorubicin; allogeneic hematopoietic stem cell transplantation; therapy effect; molecular biology; protein inhibitor; induction chemotherapy; recurrence free survival; randomized controlled trial (topic); isocitrate dehydrogenase 1; drug; comparative effectiveness; midostaurin; acute myeloid leukemia; intensive induction chemotherapy; gemtuzumab; high throughput sequencing; hypomethylating agent; isocitrate dehydrogenase 2; quizartinib; human; liposomal cytarabine; ozogamicin; venetoclax; protein b cell lymphoma 2 inhibitor
Journal Title: American Journal of Hematology
Volume: 99
Issue: 8
ISSN: 0361-8609
Publisher: John Wiley & Sons, Inc.  
Date Published: 2024-08-01
Start Page: 1640
End Page: 1643
Language: English
DOI: 10.1002/ajh.27366
PUBMED: 38751104
PROVIDER: scopus
DOI/URL:
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PubMed record and PDF -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Eytan Moshe Stein
    342 Stein
  2. Aaron David Goldberg
    106 Goldberg